Clinical Trials Browser

Phase 2 × lorlatinib × 30 days × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT07415005 2026-02-17

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Advanced Non-Small Cell Lung Cancer